Merck (MRK) PT Raised to $132 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St set to open higher after inflation data, earnings boost
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Merck (MRK) PT Raised to $135 at BMO Capital
February 4, 2026 5:43 AM ESTBMO Capital analyst Evan David Seigerman raised the price target on Merck (NYSE: MRK) to $135.00 (from $130.00) while maintaining a Outperform rating.
The analyst comments "Potential Keytruda IP protection through November 2029 could further smooth revenue declines associated with the Keytruda LOE. On today's call,... More
Merck shares fall as 2026 guidance disappoints despite solid Q4 results
February 3, 2026 6:48 AM ESTInvesting.com -- Merck & Co. (NYSE: MRK) shares have dropped 1.6% premarket on Tuesday after the pharmaceutical giant issued 2026 guidance below analyst expectations, overshadowing solid fourth-quarter results that met earnings forecasts and slightly exceeded revenue estimates.
The company reported fourth-quarter adjusted earnings of $2.04 per share, matching analyst expectations, while revenue rose 5% to $16.4 billion, surpassing the consensus estimate of $16.18 billion. Revenue... More
Merck's 2026 outlook clouds upbeat fourth-quarter results
February 3, 2026 6:34 AM ESTBy Michael Erman and Mariam Sunny
Feb 3 (Reuters) - Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates, saying the imminent loss of exclusivity on diabetes drug Januvia and other legacy medicines will impact more than analysts expect.
The weaker-than-anticipated outlook overshadowed a solid fourth quarter, in which the U.S. drugmaker beat profit and sales expectations on strong demand for its blockbuster cancer immunotherapy Keytruda.
The company expects 2026 revenue of $65.5 billion to $67.0 billion, with the top end below the average analyst estimate of $67.6 billion, according to LSEG data.
BMO Capital analyst Evan Seigerman said... More
Merck (MRK) Reports In-Line Q4 EPS; offers guidance
February 3, 2026 6:31 AM ESTMerck (NYSE: MRK) reported Q4 EPS of $2.04, in-line with the analyst estimate of $2.04. Revenue for the quarter came in at $16.4 billion versus the consensus estimate of $16.18 billion.
GUIDANCE:
Merck sees FY2026 EPS of $5.00-$5.15, versus the consensus of $5.63. Merck sees... More
Merck preview: focus on post-Keytruda growth path
February 2, 2026 10:00 PM ESTInvesting.com -- Merck (NYSE: MRK) fourth-quarter results are expected to frame how the company plans to manage looming Keytruda declines and reset its growth narrative into 2026.
BMO said the quarter should mark an inflection point, with management likely to lay out early revenue expectations for several new launches that are central to Mercks longer-term outlook.
Those include enlicitide, Ohtuvayre and Enflonsia, which BMO... More
Merck (MRK) call put ratio 2.1 calls to 1 put into quarter results
February 2, 2026 10:26 AM ESTMerck (NYSE: MRK) February 6 weekly call option implied volatility is at 57, February is at 36; compared to its 52-week range of 22 to 55. Call put ratio 2.1 calls to 1 put into the expected release of quarter results before the bell on February 3.
... MoreMerck (MRK) call put ratio 1.7 calls to 1 put into quarter results
February 2, 2026 5:07 AM ESTMerck (NYSE: MRK) February 6 weekly 110 straddle priced for a move of 4.5%. Call put ratio 1.7 calls to 1 put into the expected release of quarter results before the bell on February 3.
... More